Severity
Low
FDA Drug recall · Reported December 10, 2025
Defective Container - A defect in the side-seal which allows leakage of product.
Teva Pharmaceuticals USA, Inc recalled Carton label: Testosterone Gel 1%, 2.5 grams per unit dose, CIII, 30 unit-dose packets, R… - a low-severity action.
Carton label: Testosterone Gel 1%, 2.5 grams per unit dose, CIII, 30 unit-dose packets, R… was recalled by Teva Pharmaceuticals USA, Inc in December 10, 2025. Reason: Defective Container - A defect in the side-seal which allows leakage of product.. Check the official notice for the remedy. Verify recall #D-0198-2026 with the FDA Drug before acting.
The recall
Teva Pharmaceuticals USA, Inc issued this low-severity FDA Drug recall-Defective Container - A defect in the side-seal which allows leakage of product..
Sourced from official FDA Drug enforcement records. Verify recall #D-0198-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0198-2026) was formally reported on December 10, 2025, with the manufacturer initiating the action on November 7, 2025. It is classified under Low severity (Class III), with a current status of Ongoing. Teva Pharmaceuticals USA, Inc is listed as the recalling firm, operating out of Parsippany, NJ. Federal records list the affected scope as 15,944 cartons.
The documented reason for this recall is: Defective Container - A defect in the side-seal which allows leakage of product. Distribution data in the federal record shows the product reached: U.S. Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
15,944 cartons
Related Recalls
6
5 from same agency
Carton label: Testosterone Gel 1%, 2.5 grams per unit dose, CIII, 30 unit-dose packets, Rx only, Manufactured by: Actavis Laboratories, Inc, Salt Lake City, UT 84108, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, NDC 0591-3216-30. Packet label: Testosterone Gel 1%, contains 2.5 grams, For topical use only, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054,NDC: 0591-3216-17.
Defective Container - A defect in the side-seal which allows leakage of product.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Ongoing |
| Recall number | D-0198-2026 |
| Date reported | December 10, 2025 |
| Date initiated | November 7, 2025 |
| Recalling firm | Teva Pharmaceuticals USA, Inc |
| Firm location | Parsippany, NJ |
| Affected scope | 15,944 cartons |
| Distribution | U.S. Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported December 10, 2025. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.